MiniMed (MMED) officer awarded performance RSUs and 25,253 stock options

Rhea-AI Filing Summary

MiniMed Group, Inc. officer John Gyurci reported equity compensation grants on March 9, 2026. He received 2,778 performance-based restricted stock units, each tied to one share of common stock, which vest on March 9, 2027 only if MMED’s closing price reaches at least $32.05 as of the Divestment Date defined in a March 1, 2026 separation agreement. He was also granted options on 25,253 shares of common stock at an exercise price of $18.00 per share, expiring on March 9, 2036, vesting 33% on each of March 9, 2028 and March 9, 2029, and 34% on March 9, 2030.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Gyurci John

Role See Remarks

Type	Security	Shares	Price	Value
Grant/Award	Performance-Based Restricted Stock Units	2,778	$0.00	--
Grant/Award	Employee Stock Option (Right to Buy)	25,253	$0.00	--

Holdings After Transaction: Performance-Based Restricted Stock Units — 2,778 shares (Direct); Employee Stock Option (Right to Buy) — 25,253 shares (Direct)

Footnotes (1)

1. Each performance-based restricted stock unit represents a contingent right to receive one share of MMED common stock. The performance-based restricted stock units vest on March 9, 2027, subject to MMED common stock achieving a closing price per share of at least $32.05 as of the Divestment Date (as defined in the Separation Agreement, dated March 1, 2026, by and between Medtronic Group Holding, Inc. and Kangaroo US Holdco 2, Inc.). The later of March 9, 2027 or the Divestment Date. The option vests 33% on each of March 9, 2028 and March 9, 2029, and 34% on March 9, 2030.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gyurci John

(Last) (First) (Middle)

C/O 18000 DEVONSHIRE STREET

(Street)

NORTHRIDGE CA 91325

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MiniMed Group, Inc. [ MMED ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
03/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Performance-Based Restricted Stock Units	(1)	03/09/2026		A		2,778		(1)	(2)	Common Stock	2,778	$0	2,778	D
Employee Stock Option (Right to Buy)	$18	03/09/2026		A		25,253		(3)	03/09/2036	Common Stock	25,253	$0	25,253	D

Explanation of Responses:

1. Each performance-based restricted stock unit represents a contingent right to receive one share of MMED common stock. The performance-based restricted stock units vest on March 9, 2027, subject to MMED common stock achieving a closing price per share of at least $32.05 as of the Divestment Date (as defined in the Separation Agreement, dated March 1, 2026, by and between Medtronic Group Holding, Inc. and Kangaroo US Holdco 2, Inc.).

2. The later of March 9, 2027 or the Divestment Date.

3. The option vests 33% on each of March 9, 2028 and March 9, 2029, and 34% on March 9, 2030.

Remarks:

Vice President, Chief Accounting Officer

	/s/ Bryan F. Kelly, attorney-in-fact	03/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.